

# POXEL S.A.

ISIN: FR0012432516 WKN: - Asset Class: **Stock**

## Company



2022/08/17 17:35:52

Price  
**2.68** EUR

Difference ▲ 4.08%(0.11)



## Contact Details

POXEL SA  
--  
259/261, Avenue Jean Jaurès  
69007 Lyon

Tel: 33-4-37-37-20-12  
Fax: 33-4-37-70-88-15  
Web: <http://www.poxel.com>  
E-mail: -

## Company Profile

Poxel SA operates as a clinical-stage biopharmaceutical company. The firm focuses on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as non-alcoholic steatohepatitis (NASH). Its drug candidates include Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH. The company was founded by Sébastien Bolze, Sophie Hallakou-Bozec, Pascale Fouqueray-Grellier, Pascale Malgouyres and Thomas Kuhn on March 6, 2009 and is headquartered in Lyon, France.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2021		2020		2019	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	36,337,000		45,964,000		52,888,000	
<b>Common stock capital</b>		574,000		570,000		521,000
<b>Fixed assets</b>	18,477,000		19,000,000		19,058,000	
<b>Equity capital of a company</b>		8,131,000		26,766,000		38,786,000
<b>Cash and cash equivalents</b>	28,754,000		15,587,000		18,161,000	
<b>Accrued liabilities</b>		688,000		753,000		469,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		15,901,000		16,459,000		30,849,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		30,782,000		21,739,000		2,311,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		0		0		0
<b>Total assets</b>	54,814,000	54,814,000	64,964,000	64,964,000	71,946,000	71,946,000

## Balance notes

	2021	2020	2019
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	56	53	-
<b>Equity ratio</b>	14.83%	41.20%	53.91%
<b>Debt-equity ratio</b>	574.14%	142.71%	85.49%

## Others

	2021	2020	2019
<b>Tax Expense Rate</b>	8.71%	7.23%	14.52%

**Income statement**

	<b>2021</b>	<b>2020</b>	<b>2019</b>
<b>Turnover</b>	13,397,000	6,806,000	26,557,000
<b>Net income</b>	-23,763,000	-31,858,000	-25,743,000
<b>EBIT</b>	-23,128,000	-33,056,000	-30,104,000
<b>Operating income before taxes</b>	-26,030,000	-34,339,000	-30,115,000
<b>Cash Flow</b>	-18,771,000	-26,200,000	-25,448,000
<b>Net interest income</b>	-2,902,000	-1,283,000	-11,000
<b>Research and development expenses</b>	27,479,000	29,235,000	44,550,000
<b>Income taxes</b>	-2,267,000	-2,481,000	-4,372,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	239,232	128,415	-

**Board of Directors**

Pierre Legault	Chairman of Supervisory Board
John Kozarich	Member of Supervisory Board
Janice Bourque	Member of Supervisory Board
Kumi Sato	Member of Supervisory Board
Mohammed Khoso Baluch	Member of Supervisory Board
Pascale Boissel	Member of Supervisory Board
Richard Kender	Member of Supervisory Board

**Members of Management Board**